Site growth

Site performance data that follows you between sponsors

By TrialNotice · Updated
Two clinical research site staff members taking notes during a video call with a vendor
Short answerYes, your performance can follow you. Pharmaceutical sponsors share site and investigator data through the Investigator Databank, hosted today through IQVIA's Data Query System, which has grown to nearly 20 member companies. Shared data includes past trial participation, recruitment history, enrollment rates, and startup times. Investigators can view and comment on their own information through investigatordatabank.org.

What is the Investigator Databank?

A collaboration among pharmaceutical companies to share their experience with investigators. It began with a few large sponsors, launched its data platform in 2012, and has evolved into a consortium of nearly 20 members through IQVIA's Data Query System (IQVIA). By 2014, with Novartis, Janssen, Merck, Lilly, and Pfizer as members, it covered nearly 180,000 investigators and 50,000 sites (Pfizer).

What is shared?

  • Investigator and site contact details and GCP training records (Pfizer).
  • Past trial participation and recruitment history.
  • Performance metrics such as enrollment rates and startup times (IQVIA).

Members report benefits like an average ninefold increase in investigators available for feasibility, and faster recruitment through better matching (Investigator Databank). Sponsors increasingly prefer actual site level data over public study level averages (Applied Clinical Trials).

Can you see your own record?

Yes. Investigators can access the Investigator Databank at investigatordatabank.org to view the data held on them and their site, comment on their study history, and upload training certificates and CVs that member companies recognize (Pfizer).

What should you do about it?

  1. Have each investigator review and correct their profile.
  2. Add context to weak studies, such as a protocol amendment that paused enrollment.
  3. Keep certificates and CVs current there, so startup goes faster.
  4. Treat every study as a permanent entry in your record.

How do you build a record that wins studies?

Enroll well, consistently. The metric sponsors weigh most is enrollment against target, and the sites with strong records are the ones with reliable patient sources outside their own walls. See sponsor scorecards.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. IQVIA, "Today's Investigator Databank and DQS: Welcoming the Next Generation of Consortium Members" (2025)
  2. Pfizer press release, "Global Investigator Databank expands to five pharmaceutical company members" (2014)
  3. Investigator Databank, industry collaboration overview
  4. Applied Clinical Trials, "Using Public and Private Data for Clinical Operations"

Keep reading

Two clinical research site staff members reviewing a growth plan together in a bright office
Site growth

How to grow a clinical research site: a practical playbook

Research sites grow by building a record sponsors can verify: enrollment, startup speed, and screen failure. Here is what the data says about site growth, why sponsors reuse sites, and a six step playbook.

 Research site director presenting enrollment results to sponsor representatives across a conference table
Site growth

How research sites get more studies from sponsors and CROs

Sponsors award more studies to sites that enroll reliably, start fast, and forecast honestly. Here is how sponsors choose, why new sites face a slower path, and what a site can do to win repeat work.

 Sponsor clinical operations team reviewing site maps and performance charts on a large screen
Site growth

How sponsors and CROs select clinical trial sites

Sponsors shortlist sites with historical data and epidemiology, send feasibility questionnaires, then choose on patient access, past enrollment, and startup speed. Here is the process, how it evolved, and what it means for sites.